Area of research
Infectious Diseases · Virology
Research interest
Research interests include HIV Research and Treatment, HIV/AIDS drug development and treatment, HIV/AIDS Research and Interventions, and SARS-CoV-2 and COVID-19 Research.
Bayesian estimation of HIV acquisition dates for prevention trials
Optimized SMRT-UMI protocol produces highly accurate sequence datasets from diverse populations—Application to HIV-1 quasispecies
SARS-CoV-2 Viral Replication Persists in the Human Lung for Several Weeks after Symptom Onset
Frequency, kinetics and determinants of viable SARS-CoV-2 in bioaerosols from ambulatory COVID-19 patients infected with the Beta, Delta or Omicron variants
Neutralization profiles of HIV-1 viruses from the VRC01 Antibody Mediated Prevention (AMP) trials
Pharmacokinetic serum concentrations of VRC01 correlate with prevention of HIV-1 acquisition
High monoclonal neutralization titers reduced breakthrough HIV-1 viral loads in the Antibody Mediated Prevention trials
Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern Africa
Emergence of SARS-CoV-2 Omicron lineages BA.4 and BA.5 in South Africa
The evolving SARS-CoV-2 epidemic in Africa: Insights from rapidly expanding genomic surveillance
Selection Analysis Identifies Clusters of Unusual Mutational Changes in Omicron Lineage BA.1 That Likely Impact Spike Function
Detection of a SARS-CoV-2 variant of concern in South Africa
Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization
Two Randomized Trials of Neutralizing Antibodies to Prevent HIV-1 Acquisition
Prior infection with SARS-CoV-2 boosts and broadens Ad26.COV2.S immunogenicity in a variant-dependent manner
ADCC-mediating non-neutralizing antibodies can exert immune pressure in early HIV-1 infection
Selection of HIV Envelope Strains for Standardized Assessments of Vaccine-Elicited Antibody-Dependent Cellular Cytotoxicity-Mediating Antibodies
Assessing the safety and pharmacokinetics of the anti-HIV monoclonal antibody CAP256V2LS alone and in combination with VRC07-523LS and PGT121 in South African women: study protocol for the first-in-human CAPRISA 012B phase I clinical trial
Antibody-Dependent Cellular Cytotoxicity (ADCC)-Mediating Antibodies Constrain Neutralizing Antibody Escape Pathway
Rational design and in vivo selection of SHIVs encoding transmitted/founder subtype C HIV-1 envelopes
Integrin α <sub>4</sub> β <sub>7</sub> expression on peripheral blood CD4 <sup>+</sup> T cells predicts HIV acquisition and disease progression outcomes
Genital Inflammation and the Risk of HIV Acquisition in Women
Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies
Nef-mediated down-regulation of CD4 and HLA class I in HIV-1 subtype C infection: Association with disease progression and influence of immune pressure
Comparison of Viral Env Proteins from Acute and Chronic Infections with Subtype C Human Immunodeficiency Virus Type 1 Identifies Differences in Glycosylation and CCR5 Utilization and Suggests a New Strategy for Immunogen Design
Evolution of an HIV glycan–dependent broadly neutralizing antibody epitope through immune escape